Maxim Group analyst Allen Klee has reiterated their bullish stance on WELL stock, giving a Buy rating yesterday.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Allen Klee’s rating is based on WELL Health Technologies Corp’s strong financial performance and strategic initiatives. The company reported a significant increase in adjusted EBITDA for the third quarter, surpassing both the analyst’s and consensus estimates, despite slightly missing revenue expectations. This growth was partly driven by the recognition of deferred revenue and contributions from newly consolidated entities.
Furthermore, WELL Health is focusing on expanding its Canadian clinics while planning to divest its US businesses, which is expected to streamline operations and provide capital for further acquisitions. The company’s financial position, with substantial cash reserves and free cash flow generation, supports its growth strategy. Additionally, the valuation of WELL Health appears attractive compared to its peers, justifying the Buy rating with a price target of C$8.00.
Klee covers the Technology sector, focusing on stocks such as Research Solutions, Roadzen Inc, and T Stamp, Inc. Class A. According to TipRanks, Klee has an average return of -10.2% and a 32.66% success rate on recommended stocks.
In another report released yesterday, Stifel Nicolaus also maintained a Buy rating on the stock with a C$9.00 price target.